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Non-pharmacological treatment of osteoporosis with 
Nuclear Magnetic Resonance Therapy (NMR-Therapy)
Summary
Objectives: To demonstrate the long-term effects of the therapeutic use 
of nuclear magnetic resonance (NMR) on bone mineral density (BMD) 
parameters in patients with osteoporosis.
Methods: We enrolled 103 patients aged between 45 and 89 years who 
had osteoporosis with a T-score of bone mineral density less than -2.5. All 
patients received an osteoporosis treatment with low field nuclear magnetic 
resonance using a special NMR device (MBST, MedTec, Germany) for one 
hour per day on 10 consecutive days. At baseline and 12 months after NMR 
treatment the BMD was measured by DEXA. Additionally, the levels of the 
bone turnover markers osteocalcin and bone crosslaps (b-CTX; crosslinked 
telopeptides of collagen 1) were measured by immunoassays.
Results: BMD and serum levels of osteocalcin increased significantly 
from baseline to 12 months. b-CTX remained stable.
Conclusions: Under therapeutically use of NMR-Therapy, BMD-pa-
rameters increased during 12 months after a treatment block (10 x 1h). 
Therefore, NMR-Therapy can be considered a useful alternative or supple-
ment to medical therapy in patients with osteoporosis. 
IntroductIon
The bone is metabolically active and constantly being repaired and remodelled.
The disorder osteoporosis is characterised by poor bone strength and 
increased risk of fractures due to structural deterioration of the bone.
Osteoporosis is getting more and more relevance in health policy.
Based on demographic changes (increase in older population) the 
amount of people with osteoporosis and its complications like vertebral 
body or femoral neck fracture will multiply, too. In addition to effective 
drug therapy non-pharmaceutical treatments with only few or even no 
side effects are interesting.
Osteoporosis can be prevented and treated. However, it remains un-
derestimated, underdiagnosed and undertreated (1).
Today bisphosphonates are the preferred drug therapy of osteoporo-
sis. The use of bisphosphonates for the treatment of osteoporosis is de-
scribed as a first-line therapy before any other treatment regime (2, 3). 
All bisphosphonates are associated with at least partially very harmful 
side effects, primarily gastrointestinal and kidney diseases are not un-
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Latest osteoporosis treatment is done by RANK ligand 
inhibitors – specific antibodies against signal transduction 
by „Receptor Activator of Nuclear factor Kappa B Li-
gand” (RANKL) of osteocytes – which support bone 
degeneration.
Along with an increase in proliferation of osteoblasts 
and the associated bone formation a simultaneous de-
crease in bone degeneration would be desirable.
The development of a noninvasive, nonpharmacologi-
cal therapy which can provoke positive effects on bone 
cells, improve function and movement and reduce pain 
would be valuable. Nuclear Magnetic Resonance (NMR) 
as a therapeutic form of treatment has already been devel-
oped more than 10 years ago; it characterizes a technol-
ogy that uses NMR to activate cellular metabolism and 
regenerative processes (4, 5). Clinical studies demonstrate 
effects of NMR-Therapy (NMRT) on pain relief in de-
generative rheumatic diseases (6, 7).
The influence of therapeutic nuclear magnetic reso-
nance therapy (NMRT) on osteocytes depicts an interest-
ing, alternative active principle that is used since several 
years.
To verify the effect of the therapy of osteoporosis, two 
parameters can be determined: Bone density and markers 
for bone turnover.
Accurate determination of changes in bone density is 
possible by DEXA (Dual Energy X-ray Absorptiometry) 
measurement.
Bone GLA Protein – also called Osteocalcin, a major 
noncollagenous bone matrix protein – is only known to 
be synthesized by bone forming cells. Osteocalcin can be 
determined in serum by specific enzyme immunoassays 
and has proved itself as a marker for bone turnover / bone 
formation (8). Crosslinked degradation products of col-
lagen serve as degeneration markers. These fragments of 
collagen can be determined with ELISA (Enzyme Linked 
Immunosorbend Assay) as peptidbound crosslinks like 
CTx(BCTX//Cross Laps/Beta-CrossLaps. They describe 
the resorption activity in the bone. Increased BCTX val-
ues in blood indicate enhanced bone degeneration.
MethodS
103 patients (male n = 10, female n = 93) with a mean 
age of 68.4 years were included in this open trial. The 
study was performed in the K-Center (Polyclinic / Centre 
for Osteoporosis and other bone- and joint disorders, 
head: Prof.Dr.Sc. Dalibor Krpan, Prim.Dr.Med, Zagreb, 
Croatia).
All enrolled patients suffered from osteoporosis, secured 
by DEXA measurement (T-score less than -2.5), and were 
treated 10 days with therapeutic NMRT (one hour treat-
ment per day on 10 consecutive days; using MBST Osteo-
System 700, MedTec Inc., Wetzlar, Germany).
All patients have been taking VitD3 800 I.j, continu-
ously, started more than year before they did NMR treat-
ment. Patients never used other drugs for osteoporosis. 
Times of measurement was baseline and 12 months after 
NMRT.
Parameters of DEXA measurement: Changes of T-
Score, Z-Score, Bone Mineral Density (BMD) of inter-
trochanteric area, greater trochanter, ward’s triangle, fe-
mur neck and lumbar vertebra (L1 – L4).
All DXA measurements have been done on the same 
device by same technician on the DXA device, Discovery, 
QDR series (Hologic Inc., USA).
Table 1
Effect of NMRT on Bone mineral density (DEXA).
T-score baseline 12 months
significance
area mean ± SD median mean ± SD median
L1 -2.0 ± 1.23 -2.4 -1.9 ± 1.22 -2.1 p < 0.005 
L2 -2.2 ± 1.07 -2.6 -2.1 ± 1.22 -2.2 p < 0.005 
L3 -2.3 ± 1.30 -2.5 -2.0 ± 1.32 -2.0 p < 0.001 
L4 -2.1 ± 1.48 -2.2 -1.9 ± 1.63 -2.3 p < 0.005 
neck -2.1 ± 0.87 -2.2 -2.1 ± 1.51 -2.0 p < 0.001 
troch -1.4 ± 0.91 -1.5 -1.4 ± 0.91 -1.4 n.s. 
inter -1.3 ± 0.82 -1.3 -1.3 ± 0.77 -1.3 n.s. 
ward -2.1 ± 0.95 -2.2 -2.1 ± 0.91 -1.9 p < 0.05 
Result of the BMD measurement by DEXA at baseline and 12 months after NMRT.
L1 – L4 = lumbar spine zone (L1, L2, L3, L4); neck = femoral neck;  troch = trochanter; inter = intertrochanteric area; ward = Ward’s triangle; mean 
plus standard deviation and median of T-scores, p indicates significant difference between baseline and 1 year
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Laboratory measurement of Osteocalcin (Osteocalcin 
(OCN)-Elecsys) and Beta cross laps (Elecsys Bone Mark-
er Assay CrossLaps have been done from serum by elec-
tro-chemoluminiscence immunoassays (ECLIA) on a 
cobas(Elecsys-analyzer (Roche Diagnostics International 
Ltd., Switzerland).
Statistical analysis of data was done by the Ludwig 
Boltzmann Institute for Rehabilitation of Internal Dis-
eases Saalfelden using the program Sigma Plot 12.3 (SPSS 
Inc., USA)
reSultS
A significance analysis with paired t-test resp. Wil-
coxon Signed Rank Sum Test showed a significant im-
provement of T-scores of the lumbar vertebra (L1 – L4) 
in the patients with osteoporosis (male and female). T-
scores at the femoral neck and the ward’s triangle also 
showed significant enhancement from baseline to 12 
months after NMRT (Table 1). Mean and median values 
demonstrate an increase of bone density. No change of 
T-score could be depicted in greater trochanter and inter-
trochanteric area.
The change of the T-score at the ward’s triangle cor-
related with a shift of the T-score in the intertrochanteric 
area and femoral neck. Improved T-score values of the 
trochanter area are associated with T-score levels of the 
femoral neck and lumbar vertebra. The difference from 
baseline to 12 months after NMRT of the T-score in the 
intertrochanteric area correlated with the T-scores of the 
femoral neck and lumbar vertebra 3, but not with the 
residual lumbar vertebrae. An improvement of the T-score 
values at the femoral neck correlated with all other en-
hancement of parameters.
The serum levels of the bone turnover marker osteocal-
cin increased significantly within the 12 months, in average 
about 55% (Figure 2). Female patients (90%) outweighed 
males. In the group of male patients (n = 10) no significance 
for this marker could be detected due to the low number 
of cases. The median, which is independent of the rela-
tively broad distribution, also showed a clear enhancement 
of the osteocalcin concentrations from 14 to 18 ng/ml.
Interestingly, a decrease in BetaCrossLaps-Levels cor-
relates with an increased T-score at the trochanter area.
Crosslaps are fragments of collagen. During bone re-
sorption in osteoporotic processes collagen is degraded 
and crosslaps (ß-CTX) are released into circulation. El-
evated levels indicate increased bone loss. We investigated 
the effects of NMRT on ß-CTX in all study patients with 
osteoporosis. The serum concentrations of Beta-Crosslaps 
remained stable at 0.3 + 0.2 (baseline as well as after 12 
months) and did not increase during 1 year, indicating 
that there was no enhanced bone loss after NMRT.
dIScuSSIon
A DEXA measurement, the „gold standard” in os-
teodensitometry (9), offers good precision and low ra-
diation exposure. The measurement points at the lumbar 
spine and the hip (proximal femur/trochanter area) are 
the most prevalent used. Hence, these sites comprising 
femoral neck, intertrochantic area, ward’s triangle and 
trochanter were included in the presented determina-
tions.
Currently the WHO recommends measuring the 
BMD of the spine and proximal femur by DEXA to di-
agnose Osteoporosis (10).
Osteoporosis is a disorder that often leads to significant 
morbidity when untreated.
Denosumab, a monoclonal antibody to RANKL, 
given twice a year, reduces the risk of vertebral, non-ver-
tebral and hip fractures in osteoporosis parallel to a per-
cent range in BMD of 6 % (lumbar spine) respectively 3 
% (total hip) after 12 months therapy (11). The significant 
improvements of BMD by bisphosphonates amount to 
2.4 – 3.7 % (risedronate or alendronate) at the hip resp. 
4.2 – 6 % at the lumbar spine after 24 (not 12!) months 
Figure 1. DEXA assessment of BMD (T-score) in 103 patients with 
osteoporosis before and 12 months after NMRT. * indicates sig-
nificant changes
Figure 2. Osteocalcin levels in serum of patients with osteoporosis at 
baseline and 12 months after NMRT in the total group and devi-
ded in males and females;
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(12). During one year surprisingly, the NMR therapy en-
hanced the BMD by the same percentage range or more 
(up to 10 %). Ipso facto, in any case the physiological bone 
loss up to 4 % can be more than offset by NMRT!
12 months after NMRT, the bone density (DEXA) 
was significantly higher and the bone formation param-
eter Osteocalcin increased as well (Figure 1, 2). Osteocal-
cin levels are consistently related to the level of bone for-
mation and therefore it is a sensitive marker in 
osteoporosis (13). In most cases of osteoporosis normal or 
slightly reduced values of Osteocalcin are found and the 
discrimination between different groups is rather poor, 
but a clear correlation exists with spontaneous bone loss 
(14, 15).
It is not routinely recommended to use bone turnover 
markers (BTMs) but baseline measurements of bone 
markers can be checked 3-6 months later to monitor re-
sponse to treatment (8).
It is interesting that one year after NMR therapy there 
could be observed a significant increase of the Osteocalcin 
levels (p < 0.001) in the total population as well as in fe-
male patients who account for 90 % of the total collective.
The small changes of Cross-Laps indicate unaltered 
bone degeneration.
A large body of evidence indicates that pulsed electro-
magnetic fields, a safe and non-invasive method, could 
promote osteogenesis. The FDA, USA approved therapy 
with pulsed electromagnetic fields as an effective method 
for osteoporosis therapy (16). Therapy with PEMF is fre-
quently confused with nuclear magnetic resonance ther-
apy which varies physically significant from PEMF by 
another magnetic field structure and the additional radio 
frequency. PEMF could also prevent bone loss through 
regulating the cytokine expression of RANKL and OPG 
in bone cells (17).
In a recent study the inhibitory effects of PEMF on 
osteopenia in rats with disuse-induced bone loss could be 
demonstrated by increased mineral apposition and bone 
formation rates over promotion of the genes of Wnt1, 
OPG, Osteocalcin, LRP5 and others (18). In contrast 
other research groups found no support for the use of 
PEMF in the treatment of osteoporosis (19).
Investigations of our working group detected influ-
ences of the NMR-Therapy on the NFAT metabolism of 
osteo – and chondrosarcoma cells (20). PEMF might also 
modulate the process of osteoclastogenesis and subse-
quent bone resorption, at least through NFAT Carbonic 
Anhydrase II (CAII) and RANK (21).
Therapeutic nuclear magnetic resonance in medicine 
characterizes a novel technology that makes use of NMR 
to activate metabolic processes and to indicate regenera-
tive processes in specifically selectable cellular tissue. The 
technology of these therapeutic nuclear magnetic devices 
differs to those using only static or pulsed magnetic fields. 
The easy-to-use therapeutic method for regenerative stim-
ulation of disturbed and irreparable cell processes is di-
rectly based on the technology behind NMR imaging 
(=MRI). The biological effect of this technology is based 
on the knowledge that cell functions are only possible if 
energy supply is assured. Deficient energy flow in endog-
enous regeneration processes unavoidably leads to cell 
death. To prevent such conditions, the incurred energy 
deficit has to be compensated by suitably measures (e.g. 
nuclear magnetic resonance).
The application of 1 hour NMR-Therapy a day on 10 
consecutive days has been found to be efficient.
Although in Germany NMR-Therapy is successfully 
adapted for the treatment of osteoporosis already more 
than 10 years, only a few clinical studies exist.
A comparable study to our investigations with DEXA 
measurements is a trial of a German group who explored 
the bone density with QCT (quantitative computer tom-
ography) 6 months after whole-body-NMRT (10 x 1h). 
After 6 months, a significant growth of the bone mineral 
content (p < 0.05) was manifested in the NMR group but 
not with bisphosphonates in the comparison group. Paral-
lel, the scores Osteoporosis Quality of Life Questionnaire, 
Fairbank Score and Roland & Morris Disability Question-
naire were reduced significantly under NMR-therapy (22).
To access NMRT on cellular processes, investigations 
of our own research group could demonstrate in microar-
ray experiments modulating NMR effects on the regula-
tion of NFAT (Nuclear Factor of Activated T-cells) me-
tabolism and the Ca2+ release in osteosarcoma cell lines 
(20, 23).
As the annual bone loss amounts physiologically to 0.5 
– 1 % and can rise up to 4 % postmenopausally (24), a 
non-drug therapy like NMRT which has shown (by 
DEXA measurement) to improve significantly decreased 
bone density can be a useful alternative or supplement to 
medical therapy in osteoporosis.
However, a randomized double blinded controlled 
trial is warranted to confirm the effects of NMR-Therapy 
on osteoporosis.
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